Flunasys-P Tablet SR is a sustained-release formulation combining Propranolol 40mg and Flunarizine 10mg, designed to provide effective management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, works by reducing heart rate, myocardial contractility, and blood pressure, thereby decreasing the frequency and severity of migraine attacks and controlling hypertension or angina. Flunarizine, a calcium channel blocker with antihistaminic properties, helps prevent migraines by inhibiting the influx of calcium ions into vascular smooth muscle and neurons, stabilizing vascular tone and reducing neuronal excitability. The sustained-release mechanism ensures a gradual and prolonged release of both active ingredients, enhancing patient compliance by reducing dosing frequency and maintaining steady plasma concentrations. Flunasys-P is indicated for the prevention of migraine headaches, particularly in patients who also require beta-blocker therapy for cardiovascular indications. It should be used under medical supervision, with caution in patients with asthma, bradycardia, or depression. Common side effects may include fatigue, dizziness, and gastrointestinal disturbances. Regular monitoring is advised to assess therapeutic efficacy and detect any adverse reactions. This combination offers a synergistic approach to migraine prevention and cardiovascular health management.